Ken Griffin Unicycive Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding UNCY
# of Institutions
31Shares Held
46.8MCall Options Held
0Put Options Held
0-
Octagon Capital Advisors LP New York, NY8.56MShares$6.93 Million0.85% of portfolio
-
Great Point Partners LLC Greenwich, CT8.56MShares$6.93 Million1.62% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$4.11 Million0.28% of portfolio
-
Walleye Capital LLC Plymouth, MN5MShares$4.05 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.47MShares$3.62 Million0.27% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $12.2M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...